Qelbree prescribing information fda?

Qelbree (viloxazine hydrochloride) is FDA-approved for ADHD. If you want the official prescribing information (the full FDA label), you can view it on the FDA’s label database or DailyMed. I can summarize key points for you if you’d like.

Where to find the FDA-prescribing information
- FDA Drugs@FDA label: search for Qelbree (viloxazine hydrochloride) on the FDA database at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- DailyMed (the official label repository): search for Qelbree viloxazine hydrochloride at https://dailymed.nlm.nih.gov/

What I can provide if you’d like a quick summary
- Indication: ADHD in pediatric patients (as of the current label, typically 6 to 17 years old; verify if you’re looking for any updates about adult use).
- Dose and administration: The label contains the exact starting dose, titration steps, and maximum daily dose. I can pull the exact numbers from the label if you want.
- Contraindications: Situations in which Qelbree should not be used.
- Warnings/precautions: Major safety topics highlighted in the label (for example, any antidepressant-class warnings like suicidality risk in children/adolescents, and other safety notes the label calls out).
- Adverse reactions: Common and serious side effects listed in the label.
- Drug interactions: Substances that may interact with viloxazine.
- Use in special populations: pregnancy, lactation, pediatric and elderly considerations, renal/hepatic impairment.
- Other labeling details: how the product is supplied, double-checking for indications, off-label use notes, and monitoring recommendations.

If you tell me which parts you want (e.g., “brief patient-friendly summary,” or “section-by-section from dosing to adverse events”), I’ll tailor a concise summary or pull the exact label language.